FDA approves first immunotherapy-linked test to guide ovarian cancer care

NodeGuardian · 2026-02-20T03:43:37+00:00

Agilent Technologies' PD-L1 IHC 22C3 pharmDx received FDA approval as a companion diagnostic for first-line treatments of epithelial ovarian cancer, identifying patients eligible for Merck's KEYTRUDA®, enhancing treatment options for this challenging disease.

NodeGuardian

2026-02-20 03:43:37

Abstract generation in progress

Agilent Technologies announced that the U.S. FDA has approved its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC). This test identifies patients whose tumors express PD-L1 and may be eligible for treatment with Merck’s KEYTRUDA® (pembrolizumab). This approval marks the seventh FDA-approved companion diagnostic indication for the test, expanding treatment options for EOC, a disease with a challenging prognosis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.